The real money is in the longer-term core trend trades. However, sometimes those opportunities can be few and far between. This is especially true in a bear market.

New drug approvals, acquisitions, and other pipeline developments are back in the spotlight in the biotech industry, following the focus on the development of vaccines and antibody treatments for COVID-19 in the last two years.

H.C. Wainwright analyst Andrew Fein reiterates a Buy rating on Bellus Health with a $28 price target after the Phase 2 RELIEF study of BLU-5937 in chronic cough did not achieve the primary endpoint of reductions in awake cough frequency.